Literature DB >> 22776076

Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: perspectives and best practices derived from experienced treatment centres.

M Escobar1, J Maahs, E Hellman, J Donkin, A Forsyth, N Hroma, G Young, L A Valentino, R Tachdjian, D L Cooper, A D Shapiro.   

Abstract

Since the 1980s, major surgical interventions in patients with congenital haemophilia with inhibitors have been performed utilizing bypassing agents for haemostatic coverage. While reports have focused on perioperative management and haemostasis, the US currently lacks consensus guidelines for the management of patients with inhibitors during the surgical procedure, and pre- and postoperatively. Many haemophilia treatment centres (HTCs) have experience with surgery in haemophilia patients, including those with inhibitors, with approximately 50% of these HTCs having performed orthopaedic procedures. The aim of this study was to present currently considered best practices for multidisciplinary care of inhibitor patients undergoing surgery in US HTCs. Comprehensive haemophilia care in the US is provided by ~130 federally designated HTCs staffed by multidisciplinary teams of healthcare professionals. Best practices were derived from a meeting of experts from leading HTCs examining the full care spectrum for inhibitor patients ranging from identification of the need for surgery through postoperative rehabilitation. HTCs face challenges in the care of inhibitor patients requiring surgery due to the limited number of surgeons willing to operate on this complex population. US centres of excellence have developed their own best practices around an extended comprehensive care model that includes preoperative planning, perioperative haemostasis and postoperative rehabilitation. Best practices will benefit patients with inhibitors and allow improvement in the overall care of these patients when undergoing surgical procedures. In addition, opportunities for further education and outcomes assessment in the care of this patient population have been identified.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22776076     DOI: 10.1111/j.1365-2516.2012.02894.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  4 in total

Review 1.  The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors.

Authors:  Giancarlo Castaman
Journal:  Blood Transfus       Date:  2017-05-16       Impact factor: 3.443

2.  Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study.

Authors:  Brendan Kleiboer; Marcus A Layer; Lorraine A Cafuir; Adam Cuker; Miguel Escobar; M Elaine Eyster; Eric Kraut; Andrew D Leavitt; Steven R Lentz; Doris Quon; Margaret V Ragni; Dianne Thornhill; Michael Wang; Nigel S Key; Tyler W Buckner
Journal:  J Thromb Haemost       Date:  2022-02-08       Impact factor: 5.824

3.  PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.

Authors:  Miguel Escobar; James Luck; Yevhenii Averianov; Jonathan Ducore; Maria Fernanda López Fernández; Adam Giermasz; Daniel P Hart; Janna Journeycake; Craig Kessler; Cindy Leissinger; Johnny Mahlangu; Laura Villarreal Martinez; Wolfgang Miesbach; Ismail Haroon Mitha; Doris Quon; Mark T Reding; Jean-François Schved; Oleksandra Stasyshyn; Kateryna V Vilchevska; Michael Wang; Jerzy Windyga; W Allan Alexander; Ahmad Al-Sabbagh; Daniel Bonzo; Ian S Mitchell; Thomas A Wilkinson; Cédric Hermans
Journal:  Haemophilia       Date:  2021-10-06       Impact factor: 4.263

4.  Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain.

Authors:  María Mareque; María Eva Mingot-Castellano; María Fernanda López-Fernández; María Teresa Álvarez-Román; Itziar Oyagüez
Journal:  Eur J Haematol       Date:  2020-04-16       Impact factor: 2.997

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.